CR20140355A - Formulaciones de antibióticos - Google Patents

Formulaciones de antibióticos

Info

Publication number
CR20140355A
CR20140355A CR20140355A CR20140355A CR20140355A CR 20140355 A CR20140355 A CR 20140355A CR 20140355 A CR20140355 A CR 20140355A CR 20140355 A CR20140355 A CR 20140355A CR 20140355 A CR20140355 A CR 20140355A
Authority
CR
Costa Rica
Prior art keywords
antibiotic formulations
suspension formulation
antibiotic
formulations
administration
Prior art date
Application number
CR20140355A
Other languages
English (en)
Inventor
Alawi Fadil Al
Karthigeyan Nanjan
Original Assignee
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140355(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer New Zealand Ltd filed Critical Bayer New Zealand Ltd
Publication of CR20140355A publication Critical patent/CR20140355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0068—Rumen, e.g. rumen bolus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación en suspensión para su administración a un animal, la formulación en suspensión incluyendo: al menos un antibiótico de cefalosporina o una sal farmacéuticamente similar de la misma; un aceite; y un disolvente de acetato de glicerina.
CR20140355A 2011-12-23 2014-07-22 Formulaciones de antibióticos CR20140355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ59738911 2011-12-23
PCT/NZ2012/000245 WO2013095166A1 (en) 2011-12-23 2012-12-21 Antibiotic formulations

Publications (1)

Publication Number Publication Date
CR20140355A true CR20140355A (es) 2014-10-29

Family

ID=48668892

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140355A CR20140355A (es) 2011-12-23 2014-07-22 Formulaciones de antibióticos

Country Status (15)

Country Link
KR (1) KR20140102319A (es)
CN (1) CN104080456A (es)
AU (1) AU2012359296B2 (es)
BR (1) BR112014014786A2 (es)
CL (1) CL2014001602A1 (es)
CO (1) CO7101241A2 (es)
CR (1) CR20140355A (es)
DO (1) DOP2014000146A (es)
IL (1) IL233299A0 (es)
MX (1) MX2014007735A (es)
MY (1) MY167596A (es)
NI (1) NI201400064A (es)
PE (1) PE20142373A1 (es)
PH (1) PH12014501384A1 (es)
WO (1) WO2013095166A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102113822B1 (ko) 2012-07-17 2020-05-22 바이엘 뉴질랜드 리미티드 주사용 항생제 제제 및 그의 이용 방법
US9452155B2 (en) 2012-07-17 2016-09-27 Bayer New Zealand Ltd Injectable antibiotic formulations and their methods of use
CA3132159C (en) 2019-03-06 2023-11-21 Zoetis Services Llc A ready-to-use injectable formulation comprising cefovecin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
CN1517090A (zh) * 2003-01-20 2004-08-04 王玉万 含抗菌药物的兽用混悬注射剂或乳剂
WO2009032843A2 (en) * 2007-09-06 2009-03-12 Auspex Pharmaceuticals, Inc. Deuterated ethambutols and their use
CN101401787B (zh) * 2008-11-19 2011-05-18 肖希龙 一种头孢噻呋长效注射液及其制备方法
CN101953889B (zh) * 2010-09-07 2013-04-10 西北农林科技大学 一种复方头孢噻呋混悬乳剂注射液及其制备方法

Also Published As

Publication number Publication date
PE20142373A1 (es) 2015-02-11
WO2013095166A1 (en) 2013-06-27
PH12014501384A1 (en) 2014-09-22
IL233299A0 (en) 2014-08-31
AU2012359296B2 (en) 2014-12-11
BR112014014786A2 (pt) 2017-06-13
CN104080456A (zh) 2014-10-01
CL2014001602A1 (es) 2014-10-24
DOP2014000146A (es) 2014-07-31
CO7101241A2 (es) 2014-10-31
NI201400064A (es) 2014-11-28
MX2014007735A (es) 2014-08-01
MY167596A (en) 2018-09-20
KR20140102319A (ko) 2014-08-21
AU2012359296A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
BR112015003376A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
AR081678A1 (es) Metodos y composiciones para administracion intratecal de arisulfatasa a
EP3016653A4 (en) Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
MX373716B (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
BR112014025041B8 (pt) Composição farmacêutica
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
AR090975A1 (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
EA201400444A1 (ru) Производные 2-оксопиперидинила
CR20140355A (es) Formulaciones de antibióticos
BR112014022687A2 (pt) Uso de uma quantidade eficaz de r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo, composição farmacêutica, r-p88 ou um sal farmaceuticamente aceitável do mesmo, ou um éster do mesmo ou um sal farmaceuticamente aceitável de um éster do mesmo
HK1212978A1 (zh) 芥子酸的新型衍生物
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
EP2722322B8 (en) 1,3-di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
BR112013019283A2 (pt) composto, fármaco, composição farmacêutica e uso
TR200904500A2 (tr) Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
UY34839A (es) Formulaciones de antibiótico